BiotechTube

SLN360 + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hyperlipidemias

Conditions

Hyperlipidemias, Dyslipidemias, Elevated Lp(a)

Trial Timeline

Nov 18, 2020 → Aug 23, 2023

NCT ID
NCT04606602

About SLN360 + Placebo

SLN360 + Placebo is a phase 1 stage product being developed by Medpace for Hyperlipidemias. The current trial status is completed. This product is registered under clinical trial identifier NCT04606602. Target conditions include Hyperlipidemias, Dyslipidemias, Elevated Lp(a).

What happened to similar drugs?

2 of 5 similar drugs in Hyperlipidemias were approved

Approved (2) Terminated (0) Active (3)
✅Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04606602Phase 1Completed

Competing Products

5 competing products in Hyperlipidemias

See all competitors
ProductCompanyStageHype Score
Evolocumab + Statins (Cardiovascular Agents)AmgenApproved
39
atorvastatin + atorvastatin + atorvastatinPfizerApproved
43
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3
34